Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study

BACKGROUND: Rat sarcoma viral oncogene homolog (RAS) gene mutation is a common molecular event in colorectal cancer (CRC). The prognosis of mCRC (metastatic colorectal cancer) patients with RAS mutation is poor and capecitabine and oxaliplatin (CapeOx) plus bevacizumab has shown to be one of the sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Xuefeng, Zhong, Chenhan, Weng, Shanshan, Hu, Hanguang, Wang, Jian, Xiao, Qian, Wang, Jianwei, Sun, Lifeng, Xu, Dong, Liao, Xiujun, Dong, Caixia, Zhang, Suzhan, Li, Jun, Ding, Kefeng, Yuan, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354966/
https://www.ncbi.nlm.nih.gov/pubmed/37464378
http://dx.doi.org/10.1186/s12885-023-11139-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354966/
https://www.ncbi.nlm.nih.gov/pubmed/37464378
http://dx.doi.org/10.1186/s12885-023-11139-z

Ejemplares similares